WebJul 26, 2024 · The good news was that DNL310 was able to quickly reduce and normalize heparan sulfate in cerebrospinal fluid (CSF). This suggests that the blood-brain barrier … WebMay 12, 2024 · This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of DNL310, an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II).

DNL310 for Hunter Syndrome Granted Fast Track Designation

WebNov 10, 2024 · About DNL310 for Hunter syndrome (MPS II) DNL310 is a fusion protein composed of the lysosomal enzyme, IDS, fused to Denali’s proprietary Enzyme Transport Vehicle (ETV), which is engineered to... Webmechanism of action: (1) The manner in which a therapeutic agent acts, which includes blocking of receptors, enzymes, stimulating hormone production, etc. (2) The physiologic or biochemical processes within the body that are affected by a drug’s action, producing a given response. hellabys ltd

Denali Therapeutics Announces Presentations on DNL310

WebJan 14, 2024 · DNL310 is intravenously administered and intended to improve overall clinical manifestations of Hunter syndrome, including both peripheral and neurological symptoms, which are not adequately... WebFeb 10, 2024 · DNL310 was generally well tolerated with the most common treatment-emergent adverse events being infusion-related reactions (IRRs). IRRs occurred in 15 of … WebThe purpose of this multi-center global clinical research study is to see if the new compound DNL310, an enzyme replacement therapy (ERT) that is thought to penetrate the central nervous system (CNS), is safe and tolerable when given to patients with mucopolysaccharidosis type II (MPS II), also called Hunter syndrome. hellaby to rotherham